MassBiologics of the University of Massachuisetts Medical School is a facility that has the distinction of being the only non-profit FDA licensed manufacturer of vaccine and biologics in the United States. The most recent addition to their capacity is a 90,000 sq ft facility, opened in May of 2010, on MassBiologics' 15.3-acre campus in Mattapan. The new facility centralizes research and development teams in state-of-the-art laboratories designed to foster collaborations and speed the pace of discovery. The new facility is adjacent to their manufacturing facility, opened in 2005, which houses state-of-the-art aseptic filling capacity and humanized monoclonal antibody manufacturing, both in short supply in the United States. These facilities allow MassBiologics to continue filling its own products as well as offering this unique resource to private and public entities.
Currently MassBiologics produces 20% of the tetanus vaccine used in the US as well as licensed immune globulin products. The mission of MassBiologics is to develop and manufacture biologic products of public health importance that target unmet medical needs and emerging public health threats. This includes products expected to have small markets due to limited incidence of disease (orphan products), uncertain markets as new infectious diseases emerge, or products for poor nations to address unique needs. New product development at MassBiologics focuses on the development of “humanized” monoclonal antibodies (MAbs) for prevention and treatment of infectious diseases.
During the last few years, monoclonal antibody development and manufacturing expertise has expanded through collaboration with public and private partners. MassBiologics has developed eight MAbs since 1998 and successfully established a product discovery group to bring MAbs from concept to clinical trials. The first four MAbs were developed (but not discovered) at MBL in collaboration with NIH or a private partner. The next four MAbs were examples of MBL’s ability of taking a product from an idea to patients. These include the rapid and timely development of two MAbs to treat hospital-acquired C. difficile diarrhea, a MAb for post-exposure rabies treatment and a MAb to control SARS.